We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Caleres
CAL
$418M
| $124K | 0.12% |
+10,000
| New | +$130K |
|
|
HELP
177
Cybin Inc
HELP
$893M
| $122K | 0.12% |
+18,500
| New | +$92.5K |
|
178
Alector
ALEC
$275M
| $122K | 0.12% |
60,509
+36,955
| +157% | +$79.2K |
|
179
Voyager Therapeutics
VYGR
$216M
| $120K | 0.12% |
+34,400
| New | +$130K |
|
180
PepGen
PEPG
$215M
| $120K | 0.12% |
66,880
+12,500
| +23% | +$20.3K |
|
181
Acumen Pharmaceuticals
ABOS
$230M
| $119K | 0.11% |
44,478
+7,200
| +19% | +$17.8K |
|
182
Spero Therapeutics
SPRO
$70.5M
| $113K | 0.11% |
51,335
+17,880
| +53% | +$46.8K |
|
183
Organogenesis Holdings
ORGO
$220M
| $113K | 0.11% |
+46,600
| New | +$114K |
|
184
Century Therapeutics
IPSC
$382M
| $113K | 0.11% |
+46,200
| New | +$106K |
|
185
Medifast
MED
$141M
| $109K | 0.1% |
10,234
-2,914
| -22% | -$33.6K |
|
186
Precision BioSciences
DTIL
$206M
| $106K | 0.1% |
+13,527
| New | +$95.2K |
|
187
Immatics
IMTX
$1.46B
| $106K | 0.1% |
+10,483
| New | +$111K |
|
188
NextCure
NXTC
$35.8M
| $96.7K | 0.09% |
60,451
+17,496
| +41% | +$129K |
|
189
Ovid Therapeutics
OVID
$547M
| $95.6K | 0.09% |
35,549
-116,370
| -77% | -$300K |
|
190
Verastem
VSTM
$743M
| $92.6K | 0.09% |
24,237
-1,882
| -7% | -$9.11K |
|
191
Taboola.com
TBLA
$1.04B
| $92.2K | 0.09% |
+18,438
| New | +$80.6K |
|
|
LENZ
192
LENZ Therapeutics
LENZ
$187M
| $90.3K | 0.09% |
+15,900
| New | +$128K |
|
193
BGSF Inc
BGSF
$58.1M
| $82.3K | 0.08% |
14,418
| – | – |
|
|
PURR
194
Hyperliquid Strategies Inc
PURR
$2.41B
| $80.5K | 0.08% |
+10,235
| New | +$75.8K |
|
195
enGene Therapeutics
ENGN
$122M
| $68K | 0.07% |
+39,300
| New | +$160K |
|
196
MacroGenics
MGNX
$280M
| $66.7K | 0.06% |
+14,431
| New | +$54.6K |
|
197
VistaGen Therapeutics
VTGN
$10.8M
| $66.3K | 0.06% |
293,343
+108,405
| +59% | +$65.4K |
|
198
Goldgroup Mining
GORO
$563M
| $64.6K | 0.06% |
51,232
+36,526
| +248% | +$49.9K |
|
199
8x8 Inc
EGHT
$273M
| $56.8K | 0.05% |
33,208
+20,939
| +171% | +$42.1K |
|
|
YRD
200
Yiren Digital
YRD
$89.2M
| $51.8K | 0.05% |
61,977
+5,674
| +10% | +$9.38K |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.